Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus DEMECLOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus DEMECLOCYCLINE HYDROCHLORIDE.
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs DEMECLOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subcitrate potassium forms a protective coating on gastric mucosa, binds to bile acids, and has antibacterial activity against Helicobacter pylori. Metronidazole inhibits nucleic acid synthesis by disrupting bacterial DNA, while tetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
For Helicobacter pylori eradication: 1 tablet (bismuth subcitrate potassium 140 mg, metronidazole 125 mg, tetracycline hydrochloride 125 mg) orally 4 times daily (with meals and at bedtime) for 14 days, plus a proton pump inhibitor.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
None Documented
None Documented
Metronidazole: 8 hours (range 6-10), prolonged in hepatic impairment; Tetracycline: 6-11 hours (normal renal function), 57-120 hours in anuria; Bismuth subcitrate: negligible systemic absorption, elimination follows transit (~24-72 hours).
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Metronidazole: 60-80% renal (as unchanged drug and metabolites), 6-15% fecal; Tetracycline: 60% renal (glomerular filtration), 40% fecal (biliary and unabsorbed); Bismuth subcitrate: >99% fecal as insoluble bismuth sulfide.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic